Table 1.
Characteristics of patients in the B3 group and non-B3 group
| Characteristics | Non-B3 (n=111) | B3 (n=90) |
| Age (yr), mean (SD) | 73.1 (12.4) | 65.6 (15.2) |
| Female, n (%) | 44 (40) | 40 (44) |
| Race, n (%) | ||
| White non-Hispanic | 91 (82) | 27 (30) |
| Black non-Hispanic | 11 (10) | 31 (34) |
| Hispanic | 5 (5) | 13 (14) |
| Asian | 2 (2) | 3 (3) |
| Other | 2 (2) | 16 (18) |
| BMI (kg/m2), mean (SD) | 30.4 (7.8) | 32.2 (7.9) |
| Baseline creatinine (mg/dl), mean (SD) | 1.17 (0.47) | 1.20 (0.55) |
| eGFR <45 ml/min per 1.73 m2 at baseline, n (%) | 24 (22) | 22 (25) |
| Past diagnoses, n (%) | ||
| COPD/asthma | 30 (27) | 13 (14) |
| Diabetes mellitus | 49 (44) | 50 (56) |
| Hypertension | 94 (85) | 70 (78) |
| HF with reduced EF | 10 (9) | 5 (6) |
| Malignancy | 17 (15) | 20 (22) |
| Current or former tobacco use | 62 (56) | 34 (39) |
| Baseline medications, n (%) | ||
| Statin | 76 (69) | 62 (69) |
| ACEi/ARB | 48 (43) | 33 (37) |
| In-hospital medications, n (%) | ||
| Hydroxychloroquine | 80 (72) | 40 (44) |
| Azithromycin | 73 (66) | 51 (57) |
| Remdesivira | 2 (2) | 11 (12) |
| Sarilumaba | 0 (0) | 18 (20) |
| Tocilizumab | 13 (12) | 10 (11) |
| Characteristics at day of eligibility | ||
| Creatinine (mg/dl), mean (SD) | 2.02 (1.35) | 2.10 (1.32) |
| KDIGO AKI stage, n (%) | ||
| Stage 1 | 85 (77) | 68 (76) |
| Stage 2 | 16 (14) | 13 (15) |
| Stage 3 | 10 (9) | 8 (9) |
| Hemoglobin (g/dl), mean (SD) | 11.4 (1.90) | 10.7 (2.19) |
| WBC count (K/μl), mean (SD) | 8.62 (4.16) | 9.41 (5.20) |
| Platelet count (K/μl), mean (SD) | 216 (108) | 255 (130) |
| Bicarbonate (mEq/L), mean (SD) | 22.6 (4.93) | 23.5 (4.97) |
| Potassium (mEq/L), mean (SD) | 4.22 (0.61) | 4.38 (0.56) |
| On vasopressors, n (%) | 34 (31) | 52 (58) |
| On mechanical ventilation, n (%) | 46 (41) | 56 (62) |
| In ICU, n (%) | 53 (48) | 63 (70) |
Non-B3, individuals not receiving niacinamide; B3, individuals receiving niacinamide; BMI, body mass index; COPD, chronic obstructive pulmonary disease; HF, heart failure; EF, ejection fraction; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; KDIGO, Kidney Disease Improving Global Outcomes; WBC, white blood cell; ICU, intensive care unit.
a
Patients were enrolled in a clinical trial of remdesivir or sarilumab, and it is unknown if they were receiving study drug or placebo.